Skip to main content
. Author manuscript; available in PMC: 2017 Jan 8.
Published in final edited form as: ACS Infect Dis. 2015 Oct 17;2(1):82–92. doi: 10.1021/acsinfecdis.5b00108

Figure 4.

Figure 4

Phase diagrams mapping the predicted trapping potency and protection as a function of NIH45-46 concentration in CVM and IgG affinity to mucins as characterized by α: (A) fraction of HIV load initially in semen that can diffuse across CVM containing NIH45-46 over the first 2 h post-deposition; (B) average number of Ab-free Env trimers on HIV arriving at the vaginal epithelium; (C, D) extent of NIH45-46-mediated protection, as quantified by infectivity relative to (C) no NIH45-46 present in CVM or (D) the same amount of NIH45-46 present but without any affinity to mucins.